Price
No data yet.
Social Signal Score
Analyst Ratings
17 analystsRevenue
$20.73M+8.68%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Rick E. Winningham
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 90
- Beta
- 0.17
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 2.01
Financials
Revenue
$20.73M+8.7%Net Income
$-5.90MEBITDA
$839.0KFree Cash Flow
$-8.88MEPS (diluted)
$-0.11Shares Outstanding (diluted)
51.67M+11.2%Operating Expenses
$18.89MCash & Debt
$387.66MReturn of Capital
$5.82MRevenue by Segment (annual)
$107.46MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $107.46M | $105.89M | $2.10 |
| 2024 | $64.38M | $-56.42M | $-1.15 |
| 2023 | $57.42M | $-55.19M | $-1.00 |
| 2022 | $51.35M | $872.13M | $-1.26 |
| 2021 | $55.31M | $-199.43M | $-2.87 |
| 2020 | $71.86M | $-278.02M | $-4.46 |
| 2019 | $73.41M | $-236.46M | $-4.25 |
| 2018 | $60.37M | $-215.52M | $-3.99 |
| 2017 | $15.39M | $-285.40M | $-5.45 |
| 2016 | $48.65M | $-190.67M | $-4.26 |
| 2015 | $42.13M | $-182.22M | $-5.34 |
| 2014 | $11.69M | $-237.04M | $-7.46 |
| 2013 | $226.0K | $-156.28M | $-4.92 |
| 2012 | $130.15M | $-9.57M | $-0.30 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $3.09
- Implied price
- $27.83
- Return from $17.03
- 10.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $13.84 — -18.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 5 | 7 | 9 | 11 | 13 |
|---|---|---|---|---|---|
| -2.0% | -11.0% | -4.8% | 0.1% | 4.2% | 7.7% |
| 3.0% | -6.5% | 0.1% | 5.2% | 9.5% | 13.2% |
| 8.0% | -1.9% | 4.9% | 10.3% | 14.8% | 18.7% |
| 13.0% | 2.6% | 9.8% | 15.4% | 20.2% | 24.2% |
| 18.0% | 7.2% | 14.6% | 20.5% | 25.5% | 29.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (4)
- Newszacks.com·26d ago·Neutral
Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue? Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsbusinesswire.com·52d ago·Neutral
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Theravance Biopharma, Inc. (NASDAQ: TBPH) to Zymeworks Inc. for $17.00 per share. Halper Sadeh encourages Theravance shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060…
View source ↗ - Newszacks.com·55d ago·Negative
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.
View source ↗ - Newsprnewswire.com·57d ago·Neutral
Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update Previously announced acquisition by Zymeworks expected to close in second half of 2026 YUPELRI ® Collaboration Revenue increased 11% year-over-year 1, from $18.7 million to $20.7 million, driven by continued Net Sales growth and improved operating leverage Organizational restructuring and cost reduction initiatives delivered 35% reduction in operating expenses year-over-year (excluding restruct
View source ↗
Earnings
Tue, Nov 10(in 5 weeks)
Consensus estimate $0.24 per share
Typical surprise -81.2% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.11 vs $0.07miss
- Thu, May 7$-0.10 vs $0.03miss
- Thu, Mar 19$0.06 vs $0.44miss
- Mon, Nov 10$0.04 vs $-0.12beat
- Tue, Aug 12$1.08 vs $-0.09beat
- Thu, May 8$-0.27 vs $-0.21miss
Estimates and results for TBPH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TBPH officers and directors.
- Bought
- —
- Sold
- $6.2m
0 trades
9 trades
- Farnum Rhondasold
- Farnum Rhondasold
- Farnum Rhondasold
- Samaha Elisold
- Samaha Elisold
- Samaha Elisold
- Farnum Rhondasold
- Farnum Rhondasold
91 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- George Whitesideshouse · CA27 · disclosed Apr 23, 2025 (30d later)Sell$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.